Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-16673 versus pirtobrutinib in relapsed/refractory CLL or SLL
NL-OMON60593Phase 3Recruiting
- Sponsor
- BeOne Medicines
- Start
- Feb 2026
- Modality
- Small Molecules, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing BGB-16673 with Pirtobrutinib (2 arms). Primary endpoint: Progression-free survival. Started Feb 2026; status: recruiting.
02
Drugs
catadegbrutinibpirtobrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON60593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60593.